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Introduction
patients with different joint diseases (1-7 used fop the development of sensitive antigcn-inhibition enzymc-immunoassays spccific for keratan sulphateand core-protein-epitopes of the large aggregating protcoglycnn.
Materials and Mcthods
Rcagcnts Scphadcx G-25, Sepharose Q, Protein-G-Sepharose, the TSK G 4000 SW column (7.5 mm X 300 mm), the TSK G SWP guardcolunin (7.5 mm X 75 mm) and preformed gels for SDS-polyacrylamidc-gcl elcctrophoresis (4-15% gradient) werc obtained from Pharmacia/LKB (Frciburg, Gcrmany). Hydroxyapatite and ZctaProbe blotling membrane wcre obtained from Bio-Rad (Munich, Germany). Polyvinylidcnefluoride blolting membranes (Fluorotrans) werc purchased from Pal l (Dreieich, Germany). High molecular mass Standards, 3-[3-cholamido-propyl)-dimethylamino]-lpropane-sulphonate (CHAPS), benzamidine hydrochloride, 6-aminohexanoic acid, phenylmcthylsulphonyl fluoride and N-ethylmaleinimide were purchased from Sigma (Deisenhofen, Germany). Diaminobenzamidine-tetrahydrochloride was from Serva (Heidelberg, Gcrmany), o-phenylencdiamine (OPD, 2 mg tablets) and rabbit-anli-mouse-Ig-antiscrum were from DAKO (Kopenhagen, Denmark). Peroxidase-conjugated streptavidin and peroxidase-conjugated goat-antibodies againsl mouse-IgG were from Dianova (Hamburg, Gcrmany). Chondroilin sulphate lyase AC (EC 4.2.2.5)
2 ), chondroitin sulphate lyase ABC (EC 4.2.2.4), keratan sulphate hydrolyase (EC 3.2.1.103), keralan sulphate endo-ß-Nacetyl-glucosaminidase (keratanase II) and the keratan sulphatespecific monoclonal antibody mAB 5D4 were obtained from Seikagaku (Tokio, Japan). Sulphosuccinimidyl-6-(biotinamido)-hexanoate (NHS-LC-biotin) was from Pierce (Munich, Germany). Polycthylene glycol 1500 (PEG 1500) and trypsin (EC 3.4.21.4) was from Boehringer Mannheim (Mannheim, Germany). All othcr reagcnts werc of analytical grade (Merck, Darmstadt, Germany).
Mclhods

Isolation and purificafion of the large aggregating proteoglycan front human arlicular cartilagc
Isolation and purification of the large aggregating proteoglycan (aggrecan) from human articular cartilage was carried out äs described (12) (13) (14) (15) and is schematically shown in figure 1. Cartilage from the fcmur condylcs of 14 donors was pooled; the age of the donors was in the ränge of 10 lo 82 years. Briefly, proteoglycans werc cxtracted from cartilage by 4 mol/1 guanidine hydrochloride, 0.05 mol/1 sodium acetate, (pH 5.8) containing 5 g/l CHAPS and the protease inhibitors benzamidine hydrochloride (0.005 mol/1), 6-aminohexanoic acid (0.1 mol/1), phenylmethylsulphonyl fluoride (0.005 mol/1), N-ethylmaleimide (0.01 mol/1), and EDTA (0.05 mol/1). The 4 mol/1 guanidine hydrochloride extract of cartilage was equilibrated with 0.05 mol/1 Tris, 0.05 mol/1 sodium acetate buffer (pH 5.8) containing 7 mol/1 urea, 0.05 mol/1 NaCl, 0.05 mol/1 LiCl, 2 g/l CHAPS and proteasc-inhibitors (0,001 mol/1 Ncthylmaleimide, 0.002 mol/1 benzamidine hydrochloride and 0.001 mol/1 phenylmethylsulphonyl fluoride) by size-exclusion chromatography on Sephadex G-25. Aggrecan was isolated by anion-exchangc chromatography on Scpharosc Q (Pharmacia/LKB, Freiburg, Germany) and further purified by hydroxyapatite chromatography. 2 (17) . For chemical deglycosylation a lyophilizied aggrecan sample was treated with trifluormethanesulphonic acid in anisole (18, 19) .
Monoclonal antibodies
Monoclonal antibodies were raised in mice according to a modified protocol of the basic outline of Köhler & Milstein (20) . Briefly: 100 g of aggrecan in a volume of 300 ! were mixed with an equal volume ofFreund's complete adjuvant and injected intraperitoneally and subcutaneously into 8 week-old B ALB/c female mice. The mice received booster injections after 6 weeks in Freund 1 * incomplete adjuvant and a final injection 3 days before the fusion. Serum titres of preimmune and immune sera were determined by the use of a slot blot enzyme-immuno assay (see below). Spleen cells of the rnouse with the highest serum titre were fused with the BALB/c myeloma X63-Ag8/653, using polyethylene glycol. Ceils were plated in 96-well plates in Dulbecco's minimal essential medium containing foetal calf serum (volume fraction 0.1) and hypoxanthine-aminopterine-thymidine. Hybridoma supernatants were tested by ELISA (see below). Hybridomas that showed a positive reaction were cloned and subcloned by limiting dilution.
Screening and characterization of monoclonal antibodies
Supernatants were tested for specific antibody against aggrecan by the use of a slot blot enzyme immuno assay on a zeta probe membrane (Bio-Rad, Munich, Germany). Briefly: 50 ng of the aggreean preparation were incubated per slot for 10 min at room temperature on a zeta probe membrane. After blocking of the membrane with blotto (20 g/l dry milk powder in phosphate buffered saline) for 2 h, 200 of hybridoma supernatants were incubated for 4 h at room temperature. Bound antibodies were detected by a peroxidase-conjugatcd second antibody firorn goat, üsing diaminobenzidine/H 2 O 2 äs Substrate. Subclass determination of tbe specific monoclonal antibodies was done by an ELISA, using subclass specific antisera (Dianova, Hamburg, Germany). Monoclonal antibodies from cell culture supernatants were purified by protein G affinity chromatography according to the manufacturer's instruotions (Pharmacia Fine Chemicals, Uppsala, Sweden).
Immunochemical characterization off he large aggregating proteoglycan
For immunoblots, aggrecan was treated either with chondroitin sulphate lyases AC/ABC, with keratan sulphate hydrolyases or with a combination of these enzymes, then subrnitted to SDS-PAGE on preformed 4-15% gradient gels (Pharmacia Phast System, Pharmacia/LKB). Subsequently they were blotted to polyvinylidenefluoride-membranes (Fluorotrans, Pall) by difftision (16) . The membrane was blocked by blotto (20 g/l dry milk powder in tris buffered saline, l h, room temperature) before incubation with monoclonal antibody (diluted appropriatQly in blocking solution) for 4 h. 
Antigen-hihibition-enzyme-immunoassay
Antibodies, specific for keratan sulphate (4B3/D10) or the aggrecan-core-protein (4G4/A10) were selected for the development of sensitive antigen-inhibition ELISAs, For dctermination of keratan sulphate the keratan sulphate-rich region of the large aggregating protcoglycan (aggrecan) was prepared. Briefly, aggrecan was digested wilh chondroitinase AC/ABC, purificd by gcl-permeationchromalography and subsequently digested with trypsin. The keratan sulphate-rich region was isolated and purified by ion-cxchange chromatography. For determination of Standard Inhibition curves, variable amounts of the unlabclled and a constant amount of the biotin-labellcd keratan sulphate-rich region were uscd. For determination of the aggrecan-core-protein content, the puriiied aggrecan was used s a Standard. Microtitre-plates (96-well, high proteinbinding capacity, Greiner, N rtingen, Germany) were coated overnight wilh 100 μΐ per well of a rabbit-anti-mouse antiserum (DAKO, Kopenhagen, Denmark) diluted l : 1000 in 0.05 mol/1 Na 2 CO 3 /NaHCO 3 buffcr (pH 9.6), containing 200 mg/1 NaN 3 . Thereafter, diluted antiserum was removed, and non-specific binding sites wcrc blocked by a solution of 20 g/l bovinc serum albumin (Behring, Marburg, Germany) in phosphate buffcred saline (200 μΐ per well, 90 min). All incubations were carried out at 37 °C in a humidified atmosphere. Specific antibodies (100 μΐ per well), diluted appropriately in blocking solution, were allowed to bind for 90 min. To remove unbound antibody, wells were washed three times (200 μΐ per well of 0.1 mol/1 ΚΗ 2 Ρθ4/Κ 2 ΗΡθ4 buffer, pH 6.5). A solution (100 μΐ) containing a mixture of biotin-labellcd and unlabellcd antigen (see below) was then added. To remove unbound antigen, wells were washed three times with 200 μΐ of 0.1 mol/1 KH 2 PO4/K 2 HPO 4 (pH 6.5). Thereafter peroxidase-conjugated streptavidin (Dianova, Hamburg, Germany), diluted in 0.2 mol/1 KH 2 PO4/K 2 HPO 4 buffer (pH 6.5), containing fetal calf serum (volume fraction 0.2) was added (100 μΐ per well, 45 min). Unbound streptavidin was removed by washing the plate 5 times (200 μΐ per well) with 0.1 mol/1 sodiurn citrate/citric acid (pH 5.0). Substrate solution (100 μΐ) was added to the wells (8 mg o-phenylenediamine dissolved in 12ml 0.1 mol/1 citrate/citric acid pH 5.0 and 5 μΐ Η 2 Ο 2 (300 g/kg). Colour development was stopped by addition of 0.5 mol/1 H 2 SO 4 (100 μΐ per well), The plates were read using an ELISA plate reader (SLT, Overrath, Germany) at a wavelength of 492 nm; absorbance at 690 nm was used for back-ground subtraction.
Antigen
To measure either the keratan sulphate content or the amount of aggrecan-core-protein present in the sample, Standard-Inhibition curves (constant amount of biotin-labelled antigen and increasing amounts of unlabelled antigen) were also determined on each plate. For measurement of keratan sulphate in the presence of serum, samples were diluted in a buffer consisting of 20 m*mol/l NaH 2 PO 4 ; 50 mmol/1 Na 2 EDTA (pH 4.5) with 10 g/l bovine serum albumin and 100 μΐ/ΐ Tween-20 prior to adding the biotin-labelled antigen (2) . For determination of core-protein levels in the presence of serum, the samples were diluted in 10 g/l bovine serum albumin in phosphate buffered saline, containing l nil/1 Tween-20 prior to adding the biotin-labelled antigen. Usually, sera were diluted l : 5, l : 10 and l : 20 in the appropriate buffcr. In both cases, sera, which had been depleted of either keratan sulphate or aggrecancore-protein, wcre uscd for determination of standard-inhibition curves (see below). The keratan sulphate content of Standard and sample is expressed s the glucosamine-contenl (nmol/1), and the amount of aggrecan-core-protein is expressed s the glycine-content (nmol/1).
Removal of keratan sulphate and aggrecan core-prolein from serum
Sera used for determination of the Standard Inhibition curves were submitted to immunosorption by either the keratan sulphatespecific or the aggrecan-core-protcin specific antibody. Briefly, a polystyrene tube was coated overnight wilh a rabbit-anti-mouscimmunogl bulin antiserum (DAKO, Kopenhagen, Denmark) diluted l : 1000 in 0.05 mol/1 Na 2 C0 3 /NaHCO 3 buffcr (pH 9.6) containing 200 mg/1 NaN 3 . Thereafter, antiserum was removed, and non-specific binding sites were blocked (2 h, 20 g/l bovine serum albumin in phosphate buffered saline) prior to adding the specific antibody diluled approprialely in the blocking solution (2 h). Unbound antibody was removed by washing the tube three times with 0.1 mol/1 KH 2 PO 4 /K 2 HPO 4 (pH 6.5) before addilion of the serum to be depleted of keratan sulphate and EDTA (final conccntration 50 mmol/1). Keralan sulphate or aggrecan-core-protein were allowed lo bind to the antibody for 8 h or overnight. Depletion of the antibody-treatcd serum was checked by slot blot enzyme immuno assay. Deplcled sera wcre aliquoted and storcd at -20 °C.
Results and Discussion
Isolation and biochemical characterization of aggrecan
Aggrecan was isolated from human articular cartilage and purified by several Chromatographie Steps ( fig. 1 ). Fractions eluting between 0.9 mol/1 NaCl and 1.9 mol/1 NaCl from the Sepharose Q column were pooled and submitted to hydroxyapatite chromatography. The sample eluting between 0.13 mol/1 and 0.17 mol/1 NaH2PO 4 from the hydroxyapatite column was submitted to size-exclusion chromatography on TSK 4000. It revealed a single sharp peak in the void volume of the Fig. 2 Gel-permeation chromatography of aggrecan on TSK G 4000 SW. Purified aggrecan was submitted to analytical size exclusion chromatography on a TSK G 4000 SW column (7.5 mm X 300 mm; precolumn TSK G SWP 7.5 mm X 75 mm), equilibrated with a 0.02 mol/1 sodium phosphate buffer (pH 6.0) contain^-ing 0.3 mol/1 NaCl and 100 mg/1 CHAPS. The sample was applied to the column and eluted at a flow rate of 0.8 ml/min. Absorbance was monitored at 210 nm (-indicated by arrows.
-
-) and 280 nm (--), V 0 and V t are column ( fig. 2) , indicating homogeneity of the isolated aggrecan. The identity of aggrecan was shown by enzymatic digestion with chondroitin sulphate lyases AC/ ABC and keratan sulphate hydrolyases. The core-protein of aggrecan was labelled with biotin prior to digestion of the glycosaminoglycan chains* rDigested and ündigested samples were submitted to SDS-PAGE (4-15% gradient) and diffusion blot onto nylon membrane. Biotin» labelled compounds were detected with avidin-peroxidase with diaminobenzidine äs Substrate. After digestion of aggrecan with a combination of the chondroitin sulphate lyases AC/ABC and keratanases, a band corresponding to M r of about 200 000, i. e. the size of aggrecan-core-protein was detected (fig. 3) ; the band above M T 200 000 is most likely due tp ineomplete remqval of the glycosaminoglycan-side chains. The same holds true for the additional band seen in figure 4c . No other bänds, indicating the presence of smaller proteoglycans, could be detected. The amino acid and hexösamine composition of aggrecan is given in table 1.
Preparation and characterization of monoclonal antibodies
The aggrecan preparation was used for immunization of mice. A series of more than 20 monoclonal antibodies was obtained. Two of these monoclonal antibodies were selected for further characterization and subsequently used for the development of enzyme-immunoassäys. To Tab. l Amino acid-and hexosarnine-content of the purified large aggregating proteoglycan frorh human artieulär cartilage. Amino acid contents are expressed in mol/1000 mol; the rhplar ratios of GalN/GIcN äs well äs (cGlcN/mol 4-cGalN/mol)/amino acid/mol are given. determine the specificity of these antibodies, native and enzymatic or chemically deglycosylated aggrecan was submitted to SDS-PAGE and Western-blot. The epitope, recognized by the monoclonal antibody mAb 4B3/D10 is completely removed by keratanase digestion ( fig. 4a ), indicating that this antibody ireacts with keratan sulphate chains present on aggrecan. In this respect the antibody seems to be similar to the pfeviously described keratan sulphate-specific monoclonal antibody mAb 5D4 ( fig.  4b ) (1) . This monoclonal antibody, and several others with the same specificity, which have been described in the meantime (2, 21) , were shown to recognize a highly sulphated epitope present at the non-^reducing end of keratan sulphate chains (8, 21-=23) . Since this epitope is a common feature of keratan sulphate chains, these antibodies reäct equally well with keratan sulphate isolated from different tissües and species (9^-11, 24, 25). In contrast, the monoclonal antibody mAb 4B3/D10 shows high specificity for the keratan sulphate chains present on aggrecan from human artieular cartilage, but little or no reactivily with kei;atan sulphate isölated from human intervertebral disc (manuscript in preparation). These fmdings indicate that the monoclonal antibody mAb 4B3/D10 recogiiizes a novel epitope on the keratan sulphate chain, which is preferentially expressed on the large aggregating proteoglycan in cartilage. ta contrast, reactivity of aggrecan with the monoclonal antibody mAb 4G4/A10 is neither influenced by enzymatic nor by chemical deglycosylation of aggrecan ( fig. 4c ), indicating that this antibody recognizes an epitope present on the core-protein of aggrecan.
Development of enzyme immunoassays specific for keratan sulphate-and coreprotein-epitopes of the large aggregating proteoglycan from human articular cartilage
In the course of chronic inflammatory and degenerative joint diseases cartilage is degraded by the action of proteases and oxygen radicals. Thefefore, proteoglycan fragments, released from the cartilage into the peripheral blood, may be useful markers of cartilage degradation.
So far> only monoclonal antibodies with a specificity similar to the monoclonal antibody mAb 5D4 have been used for the measurement of keratan sulphate in serum of patients with different joint diseases (3-7). However, using these antibodies, only a poor correlation between disease activity, cartilage destruction and the keratan sulphate levels in the serum was obtained. In contrast to these results, analysis of keratan sulphate levels in synovial fluid gave rather promising results. This might be explained by the lack of cartilage specificity of the antibodies used. Even though little is known about the metabolism of keratan sulphate, it is clear that keratan sulphate is released into the serum not only from cartilage, but also from intervertebral disc, the blood vessels and perhaps other Organs (6, (9) (10) (11) (24) (25) . Therefore, when using antibodies which do not discriminate between keratan sulphate from these different sources, analysis of keratan sulphate levels in serum might be influenced strongly by keratan sulphate from other sourees than cartilage. In contrast, analysis of keratan sulphate in synovial fluid, which is released mainly from cartilage, is affected only slightly by keratan sulphate from other origins.
Therefore, the use of monoclonal antibodies with high specificity for epitopes expressed exclusively or at least preferentially on keratan sulphate chains of the large aggregating proteoglycan from articular cartilage seems to be necessary for a specific measurement of keratan sulphate release from cartilage into the serum. Moreover, the determination of a pattern of cartilage-specific proteoglycan-epitopes, present in the serum, might give a better correlation between cartilage destructioü and disease activity than the determination based on only one epitope. We therefore made novel monoclonal antibodies with higher specificity for cartilage-specific epitopes of the large aggregating proteoglycan.
As little is known about the size and the composition of proteoglycan fragments released from cartilage (26, 27) we decided to use these antibodies for the development of a sensitive antigen-inhibition-assay. This type of assay does tiot depend on repetitive epitopes, or on the expression of two defined different epitopes on one fragment, a prerequisite for classical Sandwich immuno assays. In this type of antigen-inhibition assay a constant amount of biotin-labelled antigen is added to the sample, and competes with the unlabelled antigen present in the sample for binding to the immobilized antibody. Biotinlabelled antigen, bound to the antibody, is detected by the use of streptavidin-peroxidase and o-phenylene diamine äs Substrate. An example of the standard-inhibition curves for both assays described is shown in figure5 .
One major point, which has not been adressed properly in previous work, is the interaction of keratan sulphate with serum components. In fact, strong interactions between serum and keratan sulphate have been observed. This has been successfully overcome by the use of either 50 mmol/1 EDTA and 100 / Tween-20 (4B3/D10) or 50 mmol/1 EDTA and l ml/l Tween-20 (5D4) in the sample buffer. The observation that Tween-20 and EDTA are required for counteracting the interaction between keratan sulphate and serum points to a Ca 2+ -dependent interaction. In the case of the core-proteinspecific antibody, there is virtually no interaction between the matrix and the large proteoglycan added. The keratan sulphate content of the Standard is expressed äs the molar amount of glucosamine rather than äs g/l of keratan sulphate; the core-protein-content of the Standard is expressed äs the molar amount of glycine. In our opinion, expressing the keratan sulphate-content äs glucosamine-content reflects more closely the real keratan sulphate-content, since the keratan sulphate-specific antibodies recognize epitopes containing at least one °g lucosamine-residue. Another important point when considering the specificity of the assay is the source of antigen used, because different binding affinities for antigens will greatly influence the outcome of the assay (6, 10) . In our opinion it is absolutely necessary to use aggrecan from human articular cartilage äs competing labelled antigen in this type of assay.
The reliability of these assays was analysed with respect to sensitivity and precision. For the within-run-and between-rtm imprecision coefficieüt of Variation (GV) values of < 10% were obtained. The CV values were determined for keratan sulphate concentrations of 1790 nmol/1 (l : 5 diluted serum, n = 10, CV = 7.7%) and core-protein concentrations of 66 nmol/1 (1:5 dilüted serum, n = 10, CV = 9.9%). Under the conditipns described the lower detection limit of the assays was about 10 nmol/1 glycine (4G4/A10) and 20 nmol/1 glucosamine (5D4, 4B3/D10) respectively.
The assays described in the present report allow the sensitive determination of cartilage-specific keratan sulphate and aggrecan core protein levels in human sera and will now be used for the study of different inflammatory and degenerative joint (Jiseases. A major advantage of these novel assays lie^ in their higher cartilage specificity, which will allow the sensitive and specific detection of cartilage damage not only in synovial fluid samples (3) but also in serum samples, an essential prerequisite for a broad application of these assays. The assays will be useful in the analysis of cartilage metabolism and breakdown in joint diseases, in monitoring .disease progression, but also in the search for improved drugs. They might contribute also to an understanding of the relation of inflammation and destruction in joint diseases.
